- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of earliest event reported: August 29, 2002
--------------
WEST PHARMACEUTICAL SERVICES, INC.
--------------
(Exact name of registrant as specified in charter)
Pennsylvania 1-8036 23-1210010
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
--------------
101 Gordon Drive, P.O. Box 645, Lionville, Pennsylvania 19341-0645
--------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(610) 594-2900
--------------
(Registrant's telephone number, including area code)
---------N/A--------
(Former name or former address, if changed since last report)
-------------------------------------------------------------------------------
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
Exhibit No. Description
---------- ------------
99.1 Certification by Donald E. Morel, Jr., President
and Chief Executive Officer, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
99.2 Certification by Linda R. Altemus, Vice President
and Chief Financial Officer, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
Item 9. Regulation FD Disclosure
On August 29, 2002, Donald E. Morel, Jr., President and Chief Executive
Officer, and Linda R. Altemus, Vice President and Chief Financial Officer, of
West Pharmaceutical Services, Inc. each delivered to the Securities and Exchange
Commission ("SEC") a certification pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Copies of the
certifications of Donald E. Morel, Jr. and Linda R. Altemus are filed herewith
as Exhibits 99.1 and 99.2, respectively.
Limitation of Incorporation by Reference
In accordance with general instruction B.2 of Form 8-K, the information in
this report is furnished pursuant to Item 9 and shall not be deemed to be
"filed" for the purposes of Section 18 of the Securities Exchange Act of 1934,
or otherwise subject to the liability of that section.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
Date: August 29, 2002 By: /s/ Linda R. Altemus
------------------------------------
Linda R. Altemus
Vice President and
Chief Financial Officer
Exhibit Index
Exhibit No. Description
- ---------- -----------
99.1 Certification by Donald E. Morel, Jr., President and Chief
Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.2 Certification by Linda R. Altemus, Vice President and Chief
Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002